Pharmaceutical product for the treatment of sepsis

摘要

An antibody to tumour necrosis factor- alpha (anti-TNF) and an antibody to bacterial lipopolysaccharide (anti-LPS) used together in a neutropenic rat model of sepsis are shown to enhance survival of the rats relative to either antibody used alone. Pharmaceutical products including each of the components are therefore of utility in therapy of sepsis. The anti-LPS antibody included may be specific for the O-specific chain of a particular bacterial lipopolysaccharide (serotype specific antibody) but preferably recognises the core glycolipid of lipopolysaccharide.